cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t-lymphocytes
Cell therapyexperimental
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 24, 2014 (NCT02146924)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Glioblastoma · Phase 1
- Glioma · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Lymphoma · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Large-Cell, Immunoblastic · Phase 1
- Lymphoma, Mantle-Cell · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Lymphoma, Primary Cutaneous Anaplastic Large Cell · Phase 1
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
Mechanism of action
- Epidermal growth factor receptor erbB1Immunity, passive
EGFR immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t-lymphocytes
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05625594 | Phase 1 | Nov 22, 2022 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT03579888 | Phase 1 | Jan 31, 2019 | Intrexon, University of Texas at Houston, Ziopharm |
| NCT03389230 | Phase 1 | Aug 14, 2018 | City of Hope National Medical Center, Fortress Biotech |
| NCT02146924 | Phase 1 | Sep 24, 2014 | City of Hope National Medical Center, National Cancer Institute (NCI) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| City of Hope National Medical Center | Academic/Hospital | 3 | 3 | 1 | 2014 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 1 | 2014 |
| Fortress Biotech | For profit | 1 | 0 | 1 | 2018 |
| Intrexon | For profit | 1 | 0 | 1 | 2019 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Ziopharm | For profit | 1 | 0 | 1 | 2019 |
6 organizations
Page 1 / 1